rejuvant life tabs

Biotech Longeveron files for $30M IPO

Latest articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

New research institute focuses on science of aging

New Bakar Aging Research Institute aims to drive deeply collaborative research to enhance translational medicine, progressing novel therapies from lab to clinic to community. UC...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...
Rejuvant

Florida-based Longeveron files for a $30 million IPO, targeting aging-related conditions.

Longeveron, a Phase 2 biotech which develops cellular therapies for aging-related conditions, filed the first longevity biotech IPO of 2021 with the US Securities and Exchange Commission (SEC) earlier this month to raise up to $30 million in an initial public offering.

Longevity.Technology: Longeveron, which is based in Miami, is a clinical-stage biotech, which is developing cellular therapies with the aim of tackling specific aging-related, life-limiting and life-threatening conditions. Its lead investigational product is Lomecel-B; this is a cell-based therapy derived from culture-expanded medicinal signalling cells which have been sourced from the bone marrow of young, healthy, adult donors.

In addition, the company is currently sponsoring Phase I and II trials in Alzheimer’s disease, aging frailty, metabolic syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome.

In June the company announced a Phase II clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in Japanese patients.

Elevant

 


 

The company has booked $6 million in revenue for the 12 months period to September 2020 and plans to list on the Nasdaq under the symbol LGVN.

 


 

Longeveron was founded in 2014 by Donald Soffer and Joshua Hare. Following a seed round in autumn 2017 which raised nearly $3m, Longeveron has received funding from several grants, including $3,8m from National Institutes of Health in October 2018 and $3m from the Alzheimer’s Association in July 2019.

The company has booked $6 million in revenue for the 12 months period to September 2020 and plans to list on the Nasdaq under the symbol LGVN. Longeveron filed confidentially in November of last year with Kingswood Capital Markets as the sole bookrunner on the deal. No pricing terms have yet been disclosed.

Elevant

Mesenchymal Stem Cells research has other interests in the space; Mesoblast announced an exclusive worldwide licence and collaboration with Novartis for the development, manufacture and commercialisation of their MSC product remestemcel-L, with an initial focus on COVID-19 and ARDS.

In addition, Cellular Biomedicine Group, Inc, is developing allogeneic human adipose-derived MSC therapy, with phase II clinical trials in osteoarthritis underway and plans for a phase II trial for knee osteoarthritis, and Athersys, Inc‘s MultiStem clinical product is in phase III for ischemic stroke, and is, the company claims, the only investigational cell therapy for the treatment of ARDS that has been granted both Fast Track and RMAT designation by the FDA.

Image credit: Pavel Ignatov / Shutterstock
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

Longevity supplements report: Youth & Earth profile

Youth & Earth is keeping it natural, while slowing down aging. Over the coming weeks, we will be bringing you extracts of 11 company profiles...

Longevity supplements report: Juvenescence profile

Ahead of the launch of its first major product, Metabolic Switch, we take a look at Juvenescence. Over the coming weeks, we will be bringing...

Longevity supplements report: ChromaDex profile

We dive into ChromaDex: the company behind the successful nicotinamide riboside supplement Tru Niagen®. Over the coming weeks, we will be bringing you extracts of...
Supps report ad middle